Injectable ARVs Could End HIV Stigma for Ugandan Students, Experts Say

Young Ugandans living with HIV face a dual battle: managing the virus and confronting the social stigma that often accompanies it. According to recent estimates, approximately 170,000 adolescents and young adults between the ages of 15 and 24 are living with HIV in Uganda, accounting for about 12% of the total HIV-positive population.

The daily regimen of antiretroviral (ARV) pills can be a source of anxiety for students, particularly those in boarding schools. A poignant example is Zum, a 17-year-old Senior Four student, who had to change schools after his dorm mates discovered his ARV medication. This discovery led to fear and potential bullying, highlighting the challenges faced by learners who require daily treatment.

To address these issues, medical professionals are increasingly pushing for the adoption of injectable ARVs. These long-acting medications, administered less frequently than daily pills, offer a discreet alternative that could shield students from the potential shame and discrimination associated with openly taking medication.

Advocates suggest that injectable ARVs would not only enhance treatment adherence by simplifying the medication schedule but also significantly reduce the emotional burden on young people. By removing the daily visual reminder of their status, students could experience a greater sense of normalcy and integration within their school communities, fostering a more supportive and less stigmatizing environment.

This push for advanced treatment options signifies a hopeful step towards improving the quality of life and mental well-being for Ugandan youth living with HIV, allowing them to focus on their education and personal development without the constant shadow of stigma.